US FDA expands use of GSK's Blujepa
Digest more
GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a ...
The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory ...
We recently published 13 Best ADR Stocks to Invest In. GSK plc (NYSE:GSK) is one of the best ADR stocks. GSK plc (NYSE:GSK) ...
By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments ...
GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated ...
EMA committee recommends approval of GSK’s RSV vaccine, Arexvy for all adults 18 years and older: London, UK Saturday, December 13, 2025, 13:00 Hrs [IST] GSK plc announced that ...
The US is the best place for a business to invest, the boss of one of the UK's biggest pharmaceutical companies has said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback